Weight loss drugs are everywhere, even in cycling, but do the health benefits some are seeing outweigh the risks and dangers, and what does WADA think of them?

Retatrutide helped trial participants lose up to 28.7% of their body weight, but experts warn about excessive weight loss.

Even a cursory read of the study will likely prompt questions, but let’s take the findings at face value based on what was ...

When Terra Field started taking Wegovy for weight loss in 2022, she finally understood what satiety truly felt like. “It felt the way I thought my body should have been operating the entire time,” ...

This review is based on a screening from the Sundance Film Festival. Padraic McKinley’s first feature, a Depression-era heist western led by Ethan Hawke, is an absolute delight. At turns ...

Ozempic, Mounjaro, and Zepbound can drive impressive weight loss, but stopping them is often followed by rapid weight regain. Researchers found that people regain weight faster after quitting these ...

What started with Ozempic has become a new era in weight-loss success with blockbuster GLP-1 drugs like Wegovy and Zepbound helping fight obesity. But they’re just the beginning. New treatments that ...

Many people who use these medications don’t want to stay on them long term. But research has repeatedly shown that quitting the drugs means gaining back weight. By Dani Blum Weight-loss drugs like ...

GLP-1 has become a popular buzzword in the weight-loss community — but now some are touting "GLP-3s," claiming they are taking obesity medications to the next level. GLP-1 (glucagon-like peptide-1) ...

A 2026 Investigation Into the Mitochondria Theory, Real Results, Side Effects, and the Truth Behind the Reviews. NEW YORK, NY / ACCESS Newswire / January 9, 2026 / By early 2026, Mitolyn reviews are ...

Many people who stop using weight loss drugs will return to their previous weight within two years, a new review of existing research has found. This rate of weight regain is significantly faster than ...

At this point, millions of people in the U.S. have tried at least one of a variety of glucagonlike peptide 1 (GLP-1) receptor agonist drugs such as Zepbound or Wegovy. For some, these medications have ...